Coughing patient at physician’s appointment: step-by-step instructions for diagnosis and treatment

Capa

Citar

Texto integral

Acesso aberto Acesso aberto
Acesso é fechado Acesso está concedido
Acesso é fechado Acesso é pago ou somente para assinantes

Resumo

Article discusses the causes of cough, briefly introducing their classification, diagnostic algorithms, differential diagnosis and treatment. A clinical case of managing a patient with rhinosinusitis and exacerbation of chronic bronchitis is described.

Texto integral

Acesso é fechado

Sobre autores

Svetlana Berns

National Medical Research Center for Therapy and Preventive Medicine of the Ministry of Healthcare of Russia

Autor responsável pela correspondência
Email: svberns@yandex.ru
ORCID ID: 0000-0003-1002-1895

MD, Dr. Sci. (Medicine), professor, head of the Department of studying the pathogenetic aspects of aging, head of the Department of therapy and general medical practice

Rússia, 101990, Moscow, 10/3 Petroverigsky Lane

Marina Smirnova

National Medical Research Center for Therapy and Preventive Medicine of the Ministry of Healthcare of Russia

Email: msmirnova@gnicpm.ru
ORCID ID: 0000-0002-6208-3038

MD, PhD (Medicine), head of the Laboratory for prevention of chronic respiratory diseases of the Department of primary prevention of chronic non-infectious diseases in the health care system

Rússia, 101990, Moscow, 10/3 Petroverigsky Lane

Bibliografia

  1. Chin К.К, Jung J.Y., Lee S.W. et al. The Korean cough guideline: Recommendation and summary statement. Tuberc Respir Dis (Seoul). 2016; 79(1): 14–21. https://doi.org/10.4046/trd.2016.79.1.14. PMID: 26770230. PMCID: PMC4701789.
  2. Morice A.H., Millqvist E., Belvisi M.G. et al. Expert opinion on the cough hypersensitivity syndrome in respiratory medicine. Eur Respir J. 2014; 44(5): 1132–48. https://doi.org/10.1183/09031936.00218613. PMID: 25142479.
  3. Чучалин А.Г., Абросимов В.Н. Кашель. 4-е издание, переработанное и дополненное. М.: ГЭОТАР-Медиа. 2017: 150 с. [Chuchalin A.G., Abrosimov V.N. Cough. 4th edition, revised and expanded. Moscow: GEOTAR-Media. 2017; 150 pp. (In Russ.)]. ISBN: 978-5-9704-4293-7.
  4. GOLD Report 2023: Global strategy for prevention, diagnosis and management of COPD. URL: https://goldcopd.org/2023-gold-report-2 (date of access – 01.03.2024).
  5. Клинические рекомендации. Хроническая обструктивная болезнь легких. Российское респираторное общество. Рубрикатор клинических рекомендаций Минздрава России. 2021. ID: 603. Доступ: https://cr.minzdrav.gov.ru/schema/603_2 (дата обращения – 01.03.2024). [Clinical guidelines. Chronic obstructive pulmonary disease. Russian Respiratory Society. Rubricator of clinical guidelines of the Ministry of Healthcare of Russia. 2021. ID: 603. URL: https://cr.minzdrav.gov.ru/schema/603_2 (date of access – 01.03.2024) (In Russ.)].
  6. Miravitlles M., Anzueto A. Role of infection in exacerbations of chronic obstructive pulmonary disease. Curr Opin Pulm Med. 2015; 21(3): 278–83. https://doi.org/10.1097/MCP.0000000000000154. PMID: 25719955.
  7. Morris D.E., Cleary D.W., Clarke S.C. Secondary bacterial infections associated with influenza pandemics. Frontiers Microbiol. 2017; 8: 1041. https://doi.org/10.3389/fmicb.2017.0104117. PMID: 28690590. PMCID: PMC5481322.
  8. Оковитый С.В., Зайцев А.А., Анисимова Н.А. Фармакодинамические подходы к применению мукоактивных препаратов. Лечащий врач. 2020; (10): 6–10. [Okovity S.V., Zaitsev A.A., Anisimova N.A. Pharmacodynamic approaches to the use of mucoactive drugs. Lechaschi vrach = Attending Physician. 2020; (10): 6–10 (In Russ.)]. https://doi.org/10.26295/OS.2020.62.62.001. EDN: CNBKRI.
  9. Linssen R.S.N., Ma J., Bem R.A., Rubin B.K. Rational use of mucoactive medications to treat pediatric airway disease. Paediatr Respir Rev. 2020: 36: 8–14. https://doi.org/10.1016/j.prrv.2020.06.007. PMID: 32653467. PMCID: PMC7297155.
  10. Calzetta L., Matera M.G., Rogliani P., Cazzola M. Multifaceted activity of N-acetyl-l-cysteine in chronic obstructive pulmonary disease. Expert Rev Respir Med. 2018; 12(8): 693–708. https://doi.org/10.1080/17476348.2018.1495562. PMID: 29972340.
  11. Mokhtari V., Afsharian P., Shahhoseini M. et al. A Review on various uses of N-acetyl cysteine. Cell J. 2017; 19(1): 11–17. https://doi.org/10.22074/cellj.2016.4872. PMID: 28367412. PMCID: PMC5241507.
  12. Pei Y., Liu H., Yang Y. et al. Biological activities and potential oral applications of N-acetylcysteine: Progress and prospects. Oxid Med Cell Longev. 2018: 2018: 2835787. https://doi.org/10.1155/2018/2835787. PMID: 29849877. PMCID: PMC5937417.
  13. Dhouib I.E., Jallouli M., Annabi A. et al. A minireview on N-acetylcysteine: An old drug with new approaches. Life Sci. 2016; 151: 359–63. https://doi.org/10.1016/j.lfs.2016.03.003. PMID: 26946308.
  14. [Qu D., Ren X.X., Guo L.Y. et al. Effect of N-acetylcysteine inhalation on ventilator-associated pneumonia caused by biofilm in endotracheal tubes. Zhonghua Er Ke Za Zhi. 2016; 54(4): 278–82 (In Chinese)]. https://doi.org/10.3760/cma.j.issn.0578-1310.2016.04.010. PMID: 27055427.
  15. Aruoma O.I., Halliwell B., Hoey B.M., Butler J. The antioxidant action of N-acetylcysteine: its reaction with hydrogen peroxide, hydroxyl radical, superoxide, and hypochlorous acid. Free Radic Biol Med. 1989; 6(6): 593–97. https://doi.org/10.1016/0891-5849(89)90066-x. PMID: 2546864.
  16. Шаненова Ш.Ж., Коптлеуова А.С., Дарбаева К.С. с соавт. Клиническая эффективность N-ацетилцистеина при ХОБЛ. Медицинский журнал Западного Казахстана. 2012; (3): 260. [Shanenova Sh.Zh., Koptleuova A.S., Darbaeva K.S. et al. Clinical effectiveness of N-acetylcysteine in COPD. Meditsinskiy zhurnal Zapadnogo Kazakhstana = Medical Journal of Western Kazakhstan. 2012; (3): 260 (In Russ.)]. EDN: UITSWH.
  17. Drago L., De Vecchi E., Mattina R. et al. Activity of N-acetyl-L-cysteine against biofilm of Staphylococcus aureus and Pseudomonas aeruginosa on orthopedic prosthetic materials. Int J Artif Organs. 2018; 36(1): 39–46. https://doi.org/10.5301/ijao.5000135. PMID: 23280076.
  18. Княжеская Н.П., Новиков Ю.К., Бобков Е.В. N-ацетилцистеин (Флуимуцил®) в терапии острых и хронических заболеваний органов дыхания. Справочник поликлинического врача. 2012; (4): 56–60. [Knyazheskaya N.P., Novikov Yu.K., Bobkov E.V. N-acetylcysteine (Fluimucil®) in the treatment of acute and chronic respiratory diseases. Spravochnik poloklinicheskogo vracha = Clinician’s Reference Book. 2012; (4): 56–60 (In Russ.)]. EDN: SJIKKJ.
  19. Tenorio M.C.D.S., Graciliano N.G., Moura F.A. et al. N-Acetylcysteine (NAC): Impacts on human health. Antioxidants (Basel). 2021; 10(6): 967. https://doi.org/10.3390/antiox10060967. PMID: 34208683. PMCID: PMC8234027.
  20. Aldini G., Altomare A., Baron G. et al. N-Acetylcysteine as an antioxidant and disulphide breaking agent: the reasons why. Free Radic Res. 2018; 52(7): 751–62. https://doi.org/10.1080/10715762.2018.1468564. PMID: 29742938.
  21. Fokkens W.J., Lund V.J., Hopkins C. et al. European Position Paper on Rhinosinusitis and Nasal Polyps 2020. Rhinology. 2020; 58(Suppl S29): 1–464. https://doi.org/10.4193/Rhin20.600. PMID: 32077450.
  22. van den Broek M.F., Gudden C., Kluijfhout W.P. et al. No evidence for distinguishing bacterial from viral acute rhinosinusitis using symptom duration and purulent rhinorrhea: a systematic review of the evidence base. Otolaryngol Head Neck Surg. 2014; 150(4): 533–37. https://doi.org/10.1177/0194599814522595. PMID: 24515968.
  23. Клинические рекомендации. Острый синусит. Национальная медицинская ассоциация оториноларингологов. Рубрикатор клинических рекомендаций Минздрава России. 2021. ID: 313. Доступ: https://cr.minzdrav.gov.ru/schema/313_2 (дата обращения – 01.03.2024). [Clinical guidelines. Acute sinusitis. National Medical Association of Otolaryngologists. Rubricator of clinical guidelines of the Ministry of Healthcare of Russia. 2021. ID: 313. URL: https://cr.minzdrav.gov.ru/schema/313_2 (date of access – 01.03.2024) (In Russ.)].
  24. Яковлев С.В., Рафальский В.В., Сидоренко С.В. с соавт. Стратегия и тактика рационального применения антимикробных средств в амбулаторной практике. Евразийские клинические рекомендации. Педиатрия. Consilium medicum. 2017; (1): 17–25. [Yakovlev S.V., Rafalsky V.V., Sidorenko S.V. et al. Strategy and tactics of the rational use of antimicrobial drugs in outpatient practice. Eurasian clinical guidelines. 2016. Pediatriya. Consilium Medicum = Pediatrics. Consilium Medicum. 2017; (1): 17–25. (In Russ.)]. EDN: YPSTGH.
  25. Flamm R.K., Sader H.S., Jones R.N. Spectrum and potency of ceftaroline against leading pathogens causing community-acquired respiratory tract and skin and soft tissue infections in Latin America, 2010. Braz J Infect Dis. 2013; 17(5): 564–72. https://doi.org/10.1016/j.bjid.2013.02.008. PMID: 23916453. PMCID: PMC9425132.
  26. Кривопалов А.А., Рязанцев С.В., Еремин С.А. с соавт. К вопросу о топической антибактериальной терапии острых риносинуситов. Вестник оториноларингологии. 2019; 2: 50–56. [Krivopalov A.A., Ryazantsev S.V., Eremin S.A. et al. On the issue of topical antibacterial therapy of acute rhinosinusitis. Vestnik otorinolaringologii = Bulletin of Otorhinolaryngology. 2019; (2): 50–56 (In Russ.)]. https://doi.org/10.17116/otorino20198402150. EDN: VBNYLI.
  27. Martin B.R., Reshamwala G., Short M. Treatment of a woman with Glycyrrhiza glabra for acute sinusitis: A case report. J Chiropr Med. 2018; 17(4): 268–74. https://doi.org/10.1016/j.jcm.2018.04.005. PMID: 30846920. PMCID: PMC6391234.
  28. Яковлев С.В., Елисеева Е.В., Суворова М.П. с соавт. Стратегия и тактика рационального применения антимикробных средств в амбулаторной практике. Евразийские клинические рекомендации, 2016 г. Справочник поликлинического врача. 2017; (1): 6–53. [Yakovlev S., Eliseeva E.V., Suvorova M.P. et al. Strategy and tactics of rational use of antimicrobial agents in outpatient practice. Eurasian Clinical Guidelines. 2016. Spravochnik poloklinicheskogo vracha = Clinician`s Reference Book. 2017; (1): 6–53 (In Russ.)]. EDN: ZCNDQP.
  29. Иванчик Н.В., Сухорукова М.В., Чагарян А.Н. с соавт. In vitro активность тиамфеникола в отношении клинических изолятов Haemophilus influenzae, Streptococcus pneumoniae и Streptococcus pyogenes. Клиническая микробиология и антимикробная химиотерапия. 2021; 23(1): 92–99. [Ivanchik N.V., Sukhorukova M.V., Chagaryan A.N. et al. In vitro activity of thiamphenicol against Haemophilus influenzae, Streptococcus pneumoniae and Streptococcus pyogenes clinical isolates. Klinicheskaya mikrobiologiya i antimikrobnaya khimioterapiya = Clinical Microbiology and Antimicrobial Chemotherapy. 2021; 23(1): 92–99 (In Russ.)]. https://doi.org/10.36488/cmac.2021.1.92-99. EDN: SJKIKA.
  30. Авдеев С.Н., Гаращенко Т.И., Геппе Н.А. с соавт. Резолюция совета экспертов по вопросу использования тиамфеникола глицинат ацетилцистеината в лечении внебольничных респираторных инфекций. Клиническая микробиология и антимикробная химиотерапия. 2021; 23(2): 195–196. [Avdeev S.N., Garashchenko T.I., Geppe N.A. et al. Official statements of the board of experts on the use of topical thiamphenicol in patients with communityacquired respiratory infections. Klinicheskaya mikrobiologiya i antimikrobnaya khimioterapiya = Clinical Microbiology and Antimicrobial Chemotherapy. 2021; 23(2): 195–196 (In Russ.)]. https://doi.org/10.36488/cmac.2021.2.195-196. EDN: UJVVVW.
  31. Samuni Y., Goldstein S., Dean O.M., Berk M. The chemistry and biological activities of N-acetylcysteine. Biochim Biophys Acta. 2013; 1830(8): 4117–29. https://doi.org/10.1016/j.bbagen.2013.04.016. PMID: 23618697.
  32. Dinicola S., de Grazia S., Carlomagno G., Pintucci J.P. N-acetylcysteine as powerful molecule to destroy bacterial biofilms. A systematic review. Eur Rev Med Pharmacol Sci. 2020; 18(19): 2942–48. PMID: 25339490.
  33. Blasi F., Page C., Rossolini G.M. et al. The effect of N-acetylcysteine on biofilms: Implications for the treatment of respiratory tract infections. Respiratory Medicine. 2016; 117: 190–97. https://doi.org/10.1016/j.rmed.2016.06.015. PMID: 27492531.

Arquivos suplementares

Arquivos suplementares
Ação
1. JATS XML
Baixar
2. Fig.1.

Baixar (159KB)
Metadados
3. Fig.2.

Baixar (97KB)
Metadados
4. Fig.3.

Baixar (322KB)
Metadados
5. Fig.4.

Baixar (54KB)
Metadados
6. Fig.5.

Baixar (119KB)
Metadados

Declaração de direitos autorais © Bionika Media, 2024

Este site utiliza cookies

Ao continuar usando nosso site, você concorda com o procedimento de cookies que mantêm o site funcionando normalmente.

Informação sobre cookies